Abstract | HISTORY AND ADMISSION FINDINGS: INVESTIGATIONS: Bone marrow assessments corroborated the diagnosis of a HES. However, we were not able to detect the insertional deletion 4q12 with concomitant fusion of the FIP1L1 to the PDGFRA locus. Magnetic resonance imaging (MRI) indicated a granulomatous vasculitis, which was most likely due to the hematologic malignancy. TREATMENT AND COURSE: : Despite negativity for the FIP1L1-PDGFRA fusion gene, therapy was started with the tyrosine kinase inhibitor Imatinib. This led to a rapid normalization of eosinophilic granulocytes in the peripheral blood as well as in the bone marrow. In addition, the neurologic symptoms substantially improved. CONCLUSION:
Imatinib provides a potent therapeutic option in FIP1L1-PDGFRA negative patients suffering from HES.
|
Authors | D Wolf, G Gastl, H Rumpold |
Journal | Deutsche medizinische Wochenschrift (1946)
(Dtsch Med Wochenschr)
Vol. 129
Issue 40
Pg. 2104-6
(Oct 01 2004)
ISSN: 0012-0472 [Print] Germany |
Vernacular Title | Komplette Remission eines idiopathischen hypereosinophilen Syndroms unter Imatinib. |
PMID | 15455302
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Benzamides
- Enzyme Inhibitors
- Oncogene Proteins, Fusion
- Piperazines
- Pyrimidines
- mRNA Cleavage and Polyadenylation Factors
- Imatinib Mesylate
- FIP1L1-PDGFRA fusion protein, human
- Protein-Tyrosine Kinases
- Receptor, Platelet-Derived Growth Factor alpha
|
Topics |
- Benzamides
- Enzyme Inhibitors
(therapeutic use)
- Eosinophils
(drug effects)
- Humans
- Hypereosinophilic Syndrome
(complications, drug therapy, genetics)
- Imatinib Mesylate
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Oncogene Proteins, Fusion
- Piperazines
(therapeutic use)
- Protein-Tyrosine Kinases
(antagonists & inhibitors)
- Pyrimidines
(therapeutic use)
- Receptor, Platelet-Derived Growth Factor alpha
(genetics)
- Remission Induction
- Vasculitis, Central Nervous System
(diagnosis, etiology)
- mRNA Cleavage and Polyadenylation Factors
(genetics)
|